CURRENTLY PENDING CLAIMS

The following listing of claims will replace all prior versions, and listings, of claims in the application. This listing does not amend the claims.

Listing of claims:

1 and 2 (canceled).

3 (previously presented). A method for treating chronic pain, wherein said chronic pain is a type of neuropathic pain, said method comprising administering to a subject in need of such treatment a composition comprising a MEK inhibitor selected from a compound of the following formula (I):



(I)

wherein

W is OR_1, NR_2OR_1, NR_AR_B, $NR_2NR_AR_B$, $O(CH_2)_{2-4}NR_AR_B$, or $NR_2(CH_2)_{2-4}$ NR_AR_B;

R_1 is H, C_{1-8} alkyl, C_{3-8} alkenyl, C_{3-8} alkynyl, C_{3-8} cycloalkyl, phenyl, (phenyl)-C_{1-4} alkyl, (phenyl)C_{3-4} alkenyl, (phenyl)C_{3-4} alkynyl, (C_{3-8} cycloalkyl)C_{1-4} alkyl, (C_{3-8} cycloalkyl)C_{3-4} alkenyl, (C_{3-8} cycloalkyl)C_{3-4} alkynyl, C_{3-8} heterocyclic radical, (C_{3-8} heterocyclic radical)C_{1-4} alkyl, (C_{3-8} heterocyclic radical)-C_{3-4} alkenyl, (C_{3-8} heterocyclic radical)C_{3-4} alkynyl or $(CH_2)_{2-4}$ NR_CR_D ;

R_2 is H, C $_{1-4}$ alkyl, phenyl, C $_{3-6}$ cycloalkyl, C $_{3-6}$ heterocyclic radical, or (C $_{3-6}$ cycloalkyl) methyl;

R_A is H, C $_{1-6}$ alkyl, C $_{3-8}$ alkenyl, C $_{3-8}$ alkynyl, C $_{3-8}$ cycloalkyl, phenyl, (C $_{3-8}$ cycloalkyl)C $_{1-4}$ alkyl, (C $_{3-8}$ cycloalkyl)C $_{3-4}$ alkenyl, (C $_{3-8}$ cycloalkyl)C $_{3-4}$ alkynyl, C $_{3-8}$ heterocyclic radical, (C $_{3-8}$ heterocyclic radical)C $_{1-4}$ alkyl, (aminosulfonyl)phenyl, [(aminosulfonyl)phenyl]C $_{1-4}$ alkyl, (aminosulfonyl)C $_{1-6}$ alkyl, (aminosulfonyl)C $_{3-6}$ cycloalkyl, [(aminosulfonyl)C $_{3-6}$ cycloalkyl]C $_{1-4}$ alkyl, or $(CH_2)_{2-4}$ NR_CR_D;

R_B is H, C $_{1-8}$ alkyl, C $_{3-8}$ alkenyl, C $_{3-8}$ alkynyl, C $_{3-8}$ cycloalkyl, or phenyl;

Q is one of the following formulae (i) – (iii):



(i)



(ii)



(iii)

R_3 is H or F;

R_4 is halo, NO_2, $SO_2NR_O(CH_2)_{2-4}NR_ER_F$, $SO_2NR_ER_F$, or (CO)T;

T is C $_{1-8}$ alkyl, C $_{3-8}$ cycloalkyl, (NR_ER_F)C $_{1-4}$ alkyl, OR_F, $-NR_O(CH_2)_{2-4}$ NR_ER_F, or NR_ER_F;

Z is one of the following formulae (iv) – (viii):



(iv)



(v)



(vi)



(vii)



(viii)

one of R_5 and R_6 is H or methyl and the other of R_5 and R_6 is H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, phenyl, benzyl, or –M-E-G;

M is O, CO, SO_2, NR_J, $(CO)NR_H$, $NR_H(CO)$, $NR_H(SO_2)$, $(SO_2)NR_H$, or CH_2;

E is $(CH_2)_{1-4}$ or $(CH_2)_m O(CH_2)_p$ where $1 \leq$ (each of m and p) ≤ 3 and $2 \leq (m + p) \leq 4$; or E is absent;

G is R_K, OR_I or NR_JR_K, provided that if $p = 1$, then G is H;

R_7 is H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, $(CH_2)_{1-2}Ar$, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl,
$SO_2NR_H(CH_2)_{2-4}NR_JR_K$, $(CO)(CH_2)_{2-4}NR_JR_K$ or $(CO)NR_H(CH_2)_{2-4}NR_JR_K$;

X_1 is O, S, NR_8, or CHR_9; X_2 is O, S, or CHR_9; and X_3 is O or S; where if X_1 or X_2 is CHR_9, said compound may also be a tautomerized indole;

R_8 is H, C $_{1-4}$ alkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, $(CH_2)_{1-2}Ar$, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl, C $_{2-4}$ alkenyl, C $_{2-4}$ alkynyl, C $_{3-6}$ cycloalkyl, or (C $_{2-4}$ alkyl)NR_LR_M; provided R_7 and R_8 together have no more than 14 carbon atoms, exclusive of R_L, R_M, R_J and R_K;

R_G is C $_{1-4}$ alkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, C $_{3-4}$ alkenyl, C $_{3-4}$ alkynyl, C $_{3-6}$ cycloalkyl, $(CO)OR_P$, (C $_{2-4}$ alkyl)NR_LR_M, $(CO)NR_N(CH_2)_{2-4}NR_LR_M$, $(CO)NR_LR_M$, $(CO)(CH_2)_{2-4}$-NR_LR_M, or $(CH_2)_{1-2}Ar$, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

R_9 is C $_{1-4}$ alkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, C $_{2-4}$ alkenyl, C $_{2-4}$ alkynyl,
C $_{3-6}$ cycloalkyl, $(CO)OR_P$, (C $_{2-4}$ alkyl)NR_LR_M, $(CO)NR_N(CH_2)_{2-4}NR_LR_M$, $(CO)NR_LR_M$, $(CO)(CH_2)_{2-4}$-NR_LR_M, or $(CH_2)_{1-2}Ar'$, where Ar' is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

R_P is H, C $_{1-6}$ alkyl, phenyl, C $_{3-4}$ alkenyl, C $_{3-4}$ alkynyl, C $_{3-6}$ cycloalkyl, or $(CH_2)_{2-4}$ NR_LR_M;

R_{10} is H, methyl, halo, or NO_2;

R_{11} is H, methyl, halo, or NO_2;

each of R_C, R_D, R_E, R_F, R_I, R_J, R_K, R_L and R_M is independently selected from H,

C_{1-4} alkyl, C_{3-4} alkenyl, C_{3-4} alkynyl, C_{3-6} cycloalkyl, and phenyl; each of NR_CR_D,NR_ER_F, NR_JR_K, and NR_LR_M can also independently be morpholinyl, piperazinyl, pyrrolidinyl, or piperidinyl; and

each of R_H, R_N, and R_O is independently H, methyl, or ethyl;

wherein each hydrocarbon radical or heterocyclic radical above is optionally substituted with between 1 and 3 substituents independently selected from halo, C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{3-4} alkenyl, C_{3-4} alkynyl, phenyl, hydroxyl, amino, (amino)sulfonyl, and NO_2, wherein each substituent alkyl, cycloalkyl, alkenyl, alkynyl or phenyl is in turn optionally substituted with between 1 and 3 substituents independently selected from halo, C_{1-2} alkyl, hydroxyl, amino, and NO_2;

or a pharmaceutically acceptable salt or C_{1-7} ester thereof.

4 (previously presented). The method of claim 3, wherein said neuropathic pain is associated with one of the following: inflammation, postoperative pain, phantom limb pain, burn pain, gout, trigeminal neuralgia, acute herpetic and postherpetic pain, causalgia, diabetic neuropathy, plexus avulsion, neuroma, vasculitis, viral infection, crush injury, constriction injury, tissue injury, limb amputation, post-operative pain, and arthritis pain, inclusively.

5 and 6 (canceled).

7 (previously presented). A method for treating chronic pain, wherein said chronic pain is associated with inflammation, said method comprising administering to a subject in need of such treatment a composition comprising a MEK inhibitor selected from a compound of the following formula (I):



(I)

wherein

W is OR_1, NR_2OR_1, NR_AR_B, $NR_2NR_AR_B$, $O(CH_2)_{2-4}NR_AR_B$, or $NR_2(CH_2)_{2-4}$ NR_AR_B;

R_1 is H, C $_{1-8}$ alkyl, C $_{3-8}$ alkenyl, C $_{3-8}$ alkynyl, C $_{3-8}$ cycloalkyl, phenyl, (phenyl)-C $_{1-4}$ alkyl, (phenyl)C $_{3-4}$ alkenyl, (phenyl)C $_{3-4}$ alkynyl, (C $_{3-8}$ cycloalkyl)C $_{1-4}$ alkyl, (C $_{3-8}$ cycloalkyl)C $_{3-4}$ alkenyl, (C $_{3-8}$ cycloalkyl)C $_{3-4}$ alkynyl, C $_{3-8}$ heterocyclic radical, (C $_{3-8}$ heterocyclic radical)C $_{1-4}$ alkyl, (C $_{3-8}$ heterocyclic radical)-C $_{3-4}$ alkenyl, (C $_{3-8}$ heterocyclic radical)C $_{3-4}$ alkynyl or $(CH_2)_{2-4}$ NR_CR_D ;

R_2 is H, C $_{1-4}$ alkyl, phenyl, C $_{3-6}$ cycloalkyl, C $_{3-6}$ heterocyclic radical, or (C $_{3-6}$ cycloalkyl) methyl;

R_A is H, C $_{1-6}$ alkyl, C $_{3-8}$ alkenyl, C $_{3-8}$ alkynyl, C $_{3-8}$ cycloalkyl, phenyl, (C $_{3-8}$ cycloalkyl)C $_{1-4}$ alkyl, (C $_{3-8}$ cycloalkyl)C $_{3-4}$ alkenyl, (C $_{3-8}$ cycloalkyl)C $_{3-4}$ alkynyl, C $_{3-8}$ heterocyclic radical, (C $_{3-8}$ heterocyclic radical)C $_{1-4}$ alkyl, (aminosulfonyl)phenyl, [(aminosulfonyl)phenyl]C $_{1-4}$ alkyl, (aminosulfonyl)C $_{1-6}$ alkyl, (aminosulfonyl)C $_{3-6}$ cycloalkyl, [(aminosulfonyl)C $_{3-6}$ cycloalkyl]C $_{1-4}$ alkyl, or $(CH_2)_{2-4}$ NR_CR_D;

R_B is H, C $_{1-8}$ alkyl, C $_{3-8}$ alkenyl, C $_{3-8}$ alkynyl, C $_{3-8}$ cycloalkyl, or phenyl;

Q is one of the following formulae (i) – (iii):



(i)



(ii)



(iii)

R_3 is H or F;

R_4 is halo, NO_2, $SO_2NR_O(CH_2)_{2-4}NR_ER_F$, $SO_2NR_ER_F$, or (CO)T;

T is C_{1-8} alkyl, C_{3-8} cycloalkyl, $(NR_ER_F)C_{1-4}$ alkyl, OR_F, $-NR_O(CH_2)_{2-4}NR_ER_F$, or NR_ER_F;

Z is one of the following formulae (iv) – (viii):



(iv)



(v)



(vi)



(vii)



(viii)

one of R_5 and R_6 is H or methyl and the other of R_5 and R_6 is H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, phenyl, benzyl, or –M-E-G;

M is O, CO, SO_2, NR_J, $(CO)NR_H$, $NR_H(CO)$, $NR_H(SO_2)$, $(SO_2)NR_H$, or CH_2;

E is $(CH_2)_{1-4}$ or $(CH_2)_m O(CH_2)_p$ where $1 \leq$ (each of m and p) ≤ 3 and $2 \leq (m + p) \leq 4$; or E is absent;

G is R_K, OR_I or NR_JR_K, provided that if $p = 1$, then G is H;

R_7 is H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, $(CH_2)_{1-2}Ar$, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl,
$SO_2NR_H(CH_2)_{2-4}NR_JR_K$, $(CO)(CH_2)_{2-4}NR_JR_K$ or $(CO)NR_H(CH_2)_{2-4}NR_JR_K$;

X_1 is O, S, NR_8, or CHR_9; X_2 is O, S, or CHR_9; and X_3 is O or S; where if X_1 or X_2 is CHR_9, said compound may also be a tautomerized indole;

R_8 is H, C_{1-4} alkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, $(CH_2)_{1-2}Ar$, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl, or (C_{2-4} alkyl)NR_LR_M; provided R_7 and R_8 together have no more than 14 carbon atoms, exclusive of R_L, R_M, R_J and R_K;

R_G is C_{1-4} alkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, C_{3-4} alkenyl, C_{3-4} alkynyl, C_{3-6} cycloalkyl, $(CO)OR_P$, (C_{2-4} alkyl)NR_LR_M, $(CO)NR_N(CH_2)_{2-4}NR_LR_M$, $(CO)NR_LR_M$, $(CO)(CH_2)_{2-4}$-NR_LR_M, or $(CH_2)_{1-2}Ar$, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

R_9 is C_{1-4} alkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, C_{2-4} alkenyl, C_{2-4} alkynyl,

C_{3-6} cycloalkyl, $(CO)OR_P$, $(C_{2-4}$ alkyl$)NR_LR_M$, $(CO)NR_N(CH_2)_{2-4}NR_LR_M$, $(CO)NR_LR_M$, $(CO)(CH_2)_{2-4}$-NR_LR_M, or $(CH_2)_{1-2}Ar'$, where Ar' is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

R_P is H, C_{1-6} alkyl, phenyl, C_{3-4} alkenyl, C_{3-4} alkynyl, C_{3-6} cycloalkyl, or $(CH_2)_{2-4}$ NR_LR_M;

R_{10} is H, methyl, halo, or NO_2;

R_{11} is H, methyl, halo, or NO_2;

each of R_C, R_D, R_E, R_F, R_I, R_J, R_K, R_L and R_M is independently selected from H, C_{1-4} alkyl, C_{3-4} alkenyl, C_{3-4} alkynyl, C_{3-6} cycloalkyl, and phenyl; each of NR_CR_D,NR_ER_F, NR_JR_K, and NR_LR_M can also independently be morpholinyl, piperazinyl, pyrrolidinyl, or piperidinyl; and

each of R_H, R_N, and R_O is independently H, methyl, or ethyl;

wherein each hydrocarbon radical or heterocyclic radical above is optionally substituted with between 1 and 3 substituents independently selected from halo, C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{3-4} alkenyl, C_{3-4} alkynyl, phenyl, hydroxyl, amino, (amino)sulfonyl, and NO_2, wherein each substituent alkyl, cycloalkyl, alkenyl, alkynyl or phenyl is in turn optionally substituted with between 1 and 3 substituents independently selected from halo, C_{1-2} alkyl, hydroxyl, amino, and NO_2;
or a pharmaceutically acceptable salt or C_{1-7} ester thereof.

8 (previously presented). A method for treating chronic pain, wherein said chronic pain is associated with arthritis, said method comprising administering to

a subject in need of such treatment a composition comprising a MEK inhibitor selected from a compound of the following formula (I):



(I)

wherein

W is OR_1, NR_2OR_1, NR_AR_B, $NR_2NR_AR_B$, $O(CH_2)_{2-4}NR_AR_B$, or $NR_2(CH_2)_{2-4}NR_AR_B$;

R_1 is H, C $_{1-8}$ alkyl, C $_{3-8}$ alkenyl, C $_{3-8}$ alkynyl, C $_{3-8}$ cycloalkyl, phenyl, (phenyl)-C $_{1-4}$ alkyl, (phenyl)C $_{3-4}$ alkenyl, (phenyl)C $_{3-4}$ alkynyl, (C $_{3-8}$ cycloalkyl)C $_{1-4}$ alkyl, (C $_{3-8}$ cycloalkyl)C $_{3-4}$ alkenyl, (C $_{3-8}$ cycloalkyl)C $_{3-4}$ alkynyl, C $_{3-8}$ heterocyclic radical, (C $_{3-8}$ heterocyclic radical)C $_{1-4}$ alkyl, (C $_{3-8}$ heterocyclic radical)-C $_{3-4}$ alkenyl, (C $_{3-8}$ heterocyclic radical)C $_{3-4}$ alkynyl or $(CH_2)_{2-4}$ NR_CR_D ;

R_2 is H, C $_{1-4}$ alkyl, phenyl, C $_{3-6}$ cycloalkyl, C $_{3-6}$ heterocyclic radical, or (C $_{3-6}$ cycloalkyl) methyl;

R_A is H, C $_{1-6}$ alkyl, C $_{3-8}$ alkenyl, C $_{3-8}$ alkynyl, C $_{3-8}$ cycloalkyl, phenyl, (C $_{3-8}$ cycloalkyl)C $_{1-4}$ alkyl, (C $_{3-8}$ cycloalkyl)C $_{3-4}$ alkenyl, (C $_{3-8}$ cycloalkyl)C $_{3-4}$ alkynyl, C $_{3-8}$ heterocyclic radical, (C $_{3-8}$ heterocyclic radical)C $_{1-4}$ alkyl, (aminosulfonyl)phenyl, [(aminosulfonyl)phenyl]C $_{1-4}$ alkyl, (aminosulfonyl)C $_{1-6}$ alkyl, (aminosulfonyl)C $_{3-6}$ cycloalkyl, [(aminosulfonyl)C $_{3-6}$ cycloalkyl]C $_{1-4}$ alkyl, or $(CH_2)_{2-4}$ NR_CR_D;

R_B is H, C $_{1-8}$ alkyl, C $_{3-8}$ alkenyl, C $_{3-8}$ alkynyl, C $_{3-8}$ cycloalkyl, or phenyl;

Q is one of the following formulae (i) – (iii):



(i)



(ii)



(iii)

R_3 is H or F;

R_4 is halo, NO_2, $SO_2NR_O(CH_2)_{2-4}NR_ER_F$, $SO_2NR_ER_F$, or (CO)T;

T is C $_{1-8}$ alkyl, C $_{3-8}$ cycloalkyl, (NR_ER_F)C $_{1-4}$ alkyl, OR_F, $-NR_O(CH_2)_{2-4}NR_ER_F$, or NR_ER_F;

Z is one of the following formulae (iv) – (viii):



(iv)



(v)



(vi)



(vii)



(viii)

one of R_5 and R_6 is H or methyl and the other of R_5 and R_6 is H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, phenyl, benzyl, or –M-E-G;

M is O, CO, SO_2, NR_J, $(CO)NR_H$, $NR_H(CO)$, $NR_H(SO_2)$, $(SO_2)NR_H$, or CH_2;

E is $(CH_2)_{1-4}$ or $(CH_2)_m O(CH_2)_p$ where $1 \leq$ (each of m and p) ≤ 3 and $2 \leq (m + p) \leq 4$; or E is absent;

G is R_K, OR_I or NR_JR_K, provided that if p = 1, then G is H;

R_7 is H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, $(CH_2)_{1-2}Ar$, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl,
$SO_2NR_H(CH_2)_{2-4}NR_JR_K$, $(CO)(CH_2)_{2-4}NR_JR_K$ or $(CO)NR_H(CH_2)_{2-4}NR_JR_K$;

X_1 is O, S, NR_8, or CHR_9; X_2 is O, S, or CHR_9; and X_3 is O or S; where if X_1 or X_2 is CHR_9, said compound may also be a tautomerized indole;

R_8 is H, C_{1-4} alkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, $(CH_2)_{1-2}Ar$, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6}

cycloalkyl, or (C_{2-4} alkyl)NR_LR_M; provided R_7 and R_8 together have no more than 14 carbon atoms, exclusive of R_L, R_M, R_J and R_K;

R_G is C_{1-4} alkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, C_{3-4} alkenyl, C_{3-4} alkynyl, C_{3-6} cycloalkyl, $(CO)OR_P$, (C_{2-4} alkyl)NR_LR_M, $(CO)NR_N(CH_2)_{2-4}NR_LR_M$, $(CO)NR_LR_M$, $(CO)(CH_2)_{2-4}$-NR_LR_M, or $(CH_2)_{1-2}Ar$, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

R_9 is C_{1-4} alkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, C_{2-4} alkenyl, C_{2-4} alkynyl,
C_{3-6} cycloalkyl, $(CO)OR_P$, (C_{2-4} alkyl)NR_LR_M, $(CO)NR_N(CH_2)_{2-4}NR_LR_M$, $(CO)NR_LR_M$, $(CO)(CH_2)_{2-4}$-NR_LR_M, or $(CH_2)_{1-2}Ar'$, where Ar' is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

R_P is H, C_{1-6} alkyl, phenyl, C_{3-4} alkenyl, C_{3-4} alkynyl, C_{3-6} cycloalkyl, or $(CH_2)_{2-4}$ NR_LR_M;

R_{10} is H, methyl, halo, or NO_2;

R_{11} is H, methyl, halo, or NO_2;

each of R_C, R_D, R_E, R_F, R_I, R_J, R_K, R_L and R_M is independently selected from H, C_{1-4} alkyl, C_{3-4} alkenyl, C_{3-4} alkynyl, C_{3-6} cycloalkyl, and phenyl; each of NR_CR_D,NR_ER_F, NR_JR_K, and NR_LR_M can also independently be morpholinyl, piperazinyl, pyrrolidinyl, or piperidinyl; and

each of R_H, R_N, and R_O is independently H, methyl, or ethyl;

wherein each hydrocarbon radical or heterocyclic radical above is optionally substituted with between 1 and 3 substituents independently selected from halo,

C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{3-4} alkenyl, C_{3-4} alkynyl, phenyl, hydroxyl, amino, (amino)sulfonyl, and NO_2, wherein each substituent alkyl, cycloalkyl, alkenyl, alkynyl or phenyl is in turn optionally substituted with between 1 and 3 substituents independently selected from halo, C_{1-2} alkyl, hydroxyl, amino, and NO_2;

or a pharmaceutically acceptable salt or C_{1-7} ester thereof.

9 (previously presented). A method for treating chronic pain, wherein said chronic pain is associated with post-operative pain, said method comprising administering to a subject in need of such treatment a composition comprising a MEK inhibitor selected from a compound of the following formula (I):



(I)

wherein

W is OR_1, NR_2OR_1, NR_AR_B, $NR_2NR_AR_B$, $O(CH_2)_{2-4}NR_AR_B$, or $NR_2(CH_2)_{2-4}$ NR_AR_B;

R_1 is H, C_{1-8} alkyl, C_{3-8} alkenyl, C_{3-8} alkynyl, C_{3-8} cycloalkyl, phenyl, (phenyl)-C_{1-4} alkyl, (phenyl)C_{3-4} alkenyl, (phenyl)C_{3-4} alkynyl, (C_{3-8} cycloalkyl)C_{1-4} alkyl, (C_{3-8} cycloalkyl)C_{3-4} alkenyl, (C_{3-8} cycloalkyl)C_{3-4} alkynyl, C_{3-8} heterocyclic radical, (C_{3-8} heterocyclic radical)C_{1-4} alkyl, (C_{3-8} heterocyclic radical)-C_{3-4} alkenyl, (C_{3-8} heterocyclic radical)C_{3-4} alkynyl or $(CH_2)_{2-4}$ NR_CR_D ;

R_2 is H, C $_{1-4}$ alkyl, phenyl, C $_{3-6}$ cycloalkyl, C $_{3-6}$ heterocyclic radical, or (C $_{3-6}$ cycloalkyl) methyl;

R_A is H, C $_{1-6}$ alkyl, C $_{3-8}$ alkenyl, C $_{3-8}$ alkynyl, C $_{3-8}$ cycloalkyl, phenyl, (C $_{3-8}$ cycloalkyl)C $_{1-4}$ alkyl, (C $_{3-8}$ cycloalkyl)C $_{3-4}$ alkenyl, (C $_{3-8}$ cycloalkyl)C $_{3-4}$ alkynyl, C $_{3-8}$ heterocyclic radical, (C $_{3-8}$ heterocyclic radical)C $_{1-4}$ alkyl, (aminosulfonyl)phenyl, [(aminosulfonyl)phenyl]C $_{1-4}$ alkyl, (aminosulfonyl)C $_{1-6}$ alkyl, (aminosulfonyl)C $_{3-6}$ cycloalkyl, [(aminosulfonyl)C $_{3-6}$ cycloalkyl]C $_{1-4}$ alkyl, or $(CH_2)_{2-4}$ NR_CR_D;

R_B is H, C $_{1-8}$ alkyl, C $_{3-8}$ alkenyl, C $_{3-8}$ alkynyl, C $_{3-8}$ cycloalkyl, or phenyl;

Q is one of the following formulae (i) – (iii):



(i)



(ii)



(iii)

R_3 is H or F;

R_4 is halo, NO_2, $SO_2NR_O(CH_2)_{2-4}NR_ER_F$, $SO_2NR_ER_F$, or (CO)T;

T is C $_{1-8}$ alkyl, C $_{3-8}$ cycloalkyl, (NR_ER_F)C $_{1-4}$ alkyl, OR_F, $-NR_O(CH_2)_{2-4}$ NR_ER_F, or NR_ER_F;

Z is one of the following formulae (iv) – (viii):



(iv)



(v)



(vi)



(vii)



(viii)

one of R_5 and R_6 is H or methyl and the other of R_5 and R_6 is H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, phenyl, benzyl, or –M-E-G;

M is O, CO, SO_2, NR_J, $(CO)NR_H$, $NR_H(CO)$, $NR_H(SO_2)$, $(SO_2)NR_H$, or CH_2;

E is $(CH_2)_{1-4}$ or $(CH_2)_m O(CH_2)_p$ where $1 \leq$ (each of m and p) ≤ 3 and $2 \leq (m + p) \leq 4$; or E is absent;

G is R_K, OR_I or NR_JR_K, provided that if p = 1, then G is H;

R_7 is H, C $_{1-4}$ alkyl, C $_{2-4}$ alkenyl, C $_{2-4}$ alkynyl, C $_{3-6}$ cycloalkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, $(CH_2)_{1-2}Ar$, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl,
$SO_2NR_H(CH_2)_{2-4}NR_JR_K$, $(CO)(CH_2)_{2-4}NR_JR_K$ or $(CO)NR_H(CH_2)_{2-4}NR_JR_K$;

X_1 is O, S, NR_8, or CHR_9; X_2 is O, S, or CHR_9; and X_3 is O or S; where if X_1 or X_2 is CHR_9, said compound may also be a tautomerized indole;

R_8 is H, C $_{1-4}$ alkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, $(CH_2)_{1-2}Ar$, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl, C $_{2-4}$ alkenyl, C $_{2-4}$ alkynyl, C $_{3-6}$ cycloalkyl, or (C $_{2-4}$ alkyl)NR_LR_M; provided R_7 and R_8 together have no more than 14 carbon atoms, exclusive of R_L, R_M, R_J and R_K;

R_G is C $_{1-4}$ alkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, C $_{3-4}$ alkenyl, C $_{3-4}$ alkynyl, C $_{3-6}$ cycloalkyl, $(CO)OR_P$, (C $_{2-4}$ alkyl)NR_LR_M, $(CO)NR_N(CH_2)_{2-4}NR_LR_M$, $(CO)NR_LR_M$, $(CO)(CH_2)_{2-4}$-NR_LR_M, or $(CH_2)_{1-2}Ar$, where Ar is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

R_9 is C $_{1-4}$ alkyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, C $_{2-4}$ alkenyl, C $_{2-4}$ alkynyl,
C $_{3-6}$ cycloalkyl, $(CO)OR_P$, (C $_{2-4}$ alkyl)NR_LR_M, $(CO)NR_N(CH_2)_{2-4}NR_LR_M$, $(CO)NR_LR_M$, $(CO)(CH_2)_{2-4}$-NR_LR_M, or $(CH_2)_{1-2}Ar'$, where Ar' is phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

R_P is H, C $_{1-6}$ alkyl, phenyl, C $_{3-4}$ alkenyl, C $_{3-4}$ alkynyl, C $_{3-6}$ cycloalkyl, or $(CH_2)_{2-4}$ NR_LR_M;

R_{10} is H, methyl, halo, or NO_2;

R_{11} is H, methyl, halo, or NO_2;

each of R_C, R_D, R_E, R_F, R_I, R_J, R_K, R_L and R_M is independently selected from H, C $_{1-4}$ alkyl, C $_{3-4}$ alkenyl, C $_{3-4}$ alkynyl, C $_{3-6}$ cycloalkyl, and phenyl; each of NR_CR_D,NR_ER_F, NR_JR_K, and NR_LR_M can also independently be morpholinyl, piperazinyl, pyrrolidinyl, or piperidinyl; and

each of R_H, R_N, and R_O is independently H, methyl, or ethyl;

wherein each hydrocarbon radical or heterocyclic radical above is optionally substituted with between 1 and 3 substituents independently selected from halo, C $_{1-4}$ alkyl, C $_{3-6}$ cycloalkyl, C $_{3-4}$ alkenyl, C $_{3-4}$ alkynyl, phenyl, hydroxyl, amino, (amino)sulfonyl, and NO_2, wherein each substituent alkyl, cycloalkyl, alkenyl, alkynyl or phenyl is in turn optionally substituted with between 1 and 3 substituents independently selected from halo, C $_{1-2}$ alkyl, hydroxyl, amino, and NO_2;

or a pharmaceutically acceptable salt or C $_{1-7}$ ester thereof.

10 (previously presented). A method of claim 8, wherein Q is formula (i).

11 (original). A method of claim 10, wherein R_3 is H or fluoro.

12 (original). A method of claim 11, wherein R_4 is fluoro, chloro, or bromo.

13 (previously presented). A method of claim 8, wherein R_{10} is hydrogen, methyl, fluoro, or chloro.

14 (previously presented). A method of claim 8, wherein R_{11} is methyl, chloro, fluoro, nitro, or hydrogen.

15 (original). A method of claim 14, wherein R_{11} is H.

16 (original). A method of claim 14, wherein R_{11} is fluoro.

17 (original). A method of claim 13, wherein each of R_{10} and R_{11} is fluoro.

18 (previously presented). A method of claim 8, wherein R_1 is H, methyl, ethyl, propyl, isopropyl, isobutyl, benzyl, phenethyl, allyl, C_{3-5} alkenyl, C_{3-6} cycloalkyl, (C_{3-5} cycloalkyl)C_{1-2} alkyl, (C_{3-5} heterocyclic radical)C_{1-2} alkyl, or $(CH_2)_{2-4}NR_CR_D$.

19 (original). A method of claim 18, wherein R_1 is H or (C_{3-4} cycloalkyl)C_{1-2} alkyl.

20 (previously presented). A method of claim 8, wherein R_2 is H or methyl.

21 (previously presented). A method of claim 8, wherein R_A has at least one hydroxyl substituent.

22 (previously presented). A compound of claim 8, wherein R_A is H, methyl, ethyl, isobutyl, hydroxyethyl, phenyl, 2-piperidin-1-yl-ethyl, 2,3-dihydroxy-propyl, 3-[4-(2-hydroxyethyl)-piperazin-1-yl]-propyl, 2-pyrrolidin-1-yl-ethyl, or 2-diethylamino-ethyl; and R_B is H; or where R_B is methyl and R_A is phenyl.

23 (previously presented). A method of claim 8, wherein W is NR_AR_B or $NR_2NR_AR_B$.

24 (previously presented). A method of claim 8, wherein W is $NR_2(CH_2)_{2-4}NR_AR_B$ or $O(CH_2)_{2-3}NR_AR_B$.

25 (previously presented). A method of claim 8, wherein W is NR_2OR_1.

26 (previously presented). A method of claim 8, wherein W is OR_1.

27 (previously presented). A method of claim 8, wherein Z is formula (v).

28 (original). A method of claim 27, wherein X_1 is NR_8, and R_7 is H.

29 (previously presented). A method of claim 8, wherein said MEK inhibitor has a structure selected from: 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-1H-benzoimidazole-5-carboxylic acid.

30 (previously presented). A method of claim 8, wherein said MEK inhibitor has a structure selected from: 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-1H-benzoimidazole-5-carboxylic acid; 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-benzooxazole-5-carboxylic acid; 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-benzothiazole-5-carboxylic acid; 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-benzo[1,2,5]thiadiazole-5-carboxylic acid; 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-benzo[1,2,5]oxadiazole-5-carboxylic acid; 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-2-(2-hydroxyethyl)-1H-benzoimidazole-5-carboxylic acid; 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-2-(2-dimethylamino-ethyl)-1H-benzoimidazole-5-carboxylic acid; 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-1-acetyl-benzoimidazole-5-carboxylic acid; 8-fluoro-7-(4-iodo-2-methyl-phenylamino)-quinoxaline-6-carboxylic acid; and 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-1H-benzotriazole-5-carboxylic acid; and the corresponding hydroxamic acids and cyclopropylmethyl hydroxamates.

31 (previously presented). The method of claim 8 wherein said MEK inhibitor has a structure selected from: 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-1*H*-benzoimidazole-5-carboxylic acid cyclopropylmethoxy-amide; 7-fluoro-6-(4-

iodo-2-methyl-phenylamino)-6,7-dihydro-1*H*-benzoimidazole-5-carboxylic acid (hydrochloride); 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-1*H*-benzoimidazole-5-carboxylic acid; 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-3*H*-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide; 6-(2-chloro-4-iodo-phenylamino)-7-fluoro-1*H*-benzoimidazole-5-carboxylic acid; and 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-1*H*-benzoimidazole-5-carboxylic acid pentafluorophenyl ester.

32 (previously presented). The method of claim 8 wherein said MEK inhibitor has a structure selected from: 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-1*H*-benzoimidazole-5-carboxylic acid cyclopropylmethoxy-amide; and 7-fluoro-6-(4-iodo-2-methyl-phenylamino)-3*H*-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide.